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ABSTRACT Chronic cough is a common complaint in the general population but there are no precise
data on the incidence of, and prospectively examined risk factors for chronic cough in a population-based
setting. Therefore, we investigated the period prevalence, incidence and risk factors for chronic cough in
adult subjects.
In a prospective population-based cohort study among subjects aged ⩾45 years, data on chronic cough
were collected on two separate occasions using a standardised questionnaire. Chronic cough was defined
as daily coughing for at least 3 months duration during the preceding 2 years. Potential risk factors were
gathered by interview, physical examination and several investigations.
Of the 9824 participants in this study, 1073 (10.9%) subjects had chronic cough at baseline. The
prevalence of chronic cough increased with age and peaked in the eighth decade. In subjects aged
<70 years, chronic cough was more common in women. During an average follow-up of 6 years, 439
incident cases of chronic cough occurred with an overall incidence rate of 11.6 per 1000 person-years
(95% CI 10.6–12.8). In current smokers, the incidence of chronic cough was higher in men. In the
multivariable analysis, current smoking, gastro-oesophageal reflux disease (GORD), asthma and COPD
were identified as risk factors for chronic cough.
Chronic cough is common among adults and highly prevalent in the older population. Current
smoking, GORD, asthma and COPD are independent risk factors for chronic cough. Individuals at risk of
developing chronic cough may benefit from smoking cessation and control of the underlying disease.
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Chronic cough is a common complaint in the general population and also one of the most common
conditions for which medical care is sought [1]. Globally, it affects approximately 10% of the adult
population and is associated with impaired quality of life [2, 3]. The diagnosis and treatment of chronic
cough are challenging due to the multifactorial nature of its aetiologies [4, 5].
Most cases of chronic cough, often defined as cough lasting for ⩾3 months [6], can be explained by
common respiratory and non-respiratory disease conditions such as chronic rhinosinusitis, asthma,
chronic obstructive pulmonary disease (COPD), chronic bronchitis, obesity, gastro-oesophageal reflux
disease (GORD), lung cancer, heart failure, medications (e.g. angiotensin converting enzyme inhibitors)
and other important risk factors, such as smoking, occupational and environmental factors [7–9].
However, some patients with chronic cough do not have any identifiable underlying cause which is
consequently called idiopathic chronic cough [10]. In Europe, about half of the patients with chronic
cough do not have any known cause [11]. In the light of this evidence, chronic cough has been described
as a distinct clinical syndrome, that is, the cough hypersensitivity syndrome [12–14].
The prevalence of chronic cough differs with age, sex and geographical location. It is more common in
females and in the elderly population [15]. There are geographical differences in the prevalence of chronic
cough with an estimated prevalence of 18.1% in Oceania, 12.7% in Europe, 11.0% in America, 4.4% in
Asia and 2.3% in Africa [2, 16].
Overall, the high prevalence of chronic cough, its negative impact on daily life, diagnostic challenges and limited
therapeutic options represent a knowledge gap and obvious need for more research. Apparently, the prevalence
of chronic cough has been varyingly reported and there are no precise and prospectively analysed data on the
incidence of, and risk factors for chronic cough in the adult population under everyday circumstances [4].
Therefore, the objective of this study was to investigate the period prevalence, incidence and risk factors of
chronic cough in a large prospective population-based cohort with long-term follow-up.
Methods
Study design
The present study was conducted within the Rotterdam Study, an ongoing prospective population-based
cohort study that investigates the occurrence and determinants of chronic diseases in middle-aged and
older adults. The details and updates of the study objectives and methods have been previously reported
[17, 18]. In summary, the Rotterdam Study (RS) has approximately 15000 participants, aged ⩾45 years,
enrolled in three cycles (RS I, RS II, and RS III) from the Ommoord district, a well-defined suburb of the
city of Rotterdam, the Netherlands. Participants make follow-up visits to a specially built research centre
in the district every 4–5 years for specific examinations. Data about life-style and medical history were
collected during home interview by trained research assistants. In addition, other relevant data were
retrieved from medical records of the general practitioners (GPs), nursing homes, and prescription data
from pharmacies. The Rotterdam study was approved by the medical ethics committee of the Erasmus
Medical Center, Rotterdam, the Netherlands and by the review board of the Netherlands Ministry of
Health, Welfare and Sports (1068889-159521-PG). All participants provided written informed consent.
Study population
All participants were included in this study and consisted of respondents to the first questionnaires on
chronic cough during the home interview performed between 2002 and 2008; in particular RS-I-4, RS-II-2,
and RS-III-1. Follow-up time was defined as the time period between this round’s home interview and the
subsequent second home interview.
Identification of participants with chronic cough
Chronic cough was assessed by questionnaire and defined, in agreement with international definitions, as
cough lasting for a continuous period of 3 months or more [6]. Participants were asked the following - “In
the last 2 years, did you cough nearly daily for three consecutive months or more?” [19]. Those who
answered “no” were identified as subjects without chronic cough while participants who answered “yes”
were considered to have chronic cough at baseline. The incidence of chronic cough was investigated by
following participants: free from chronic cough at baseline until the second home interview
(questionnaire). Incident cases were defined as subjects without chronic cough at baseline who developed
chronic cough during follow-up (as evidenced at the second interview).
Covariables
Covariables were assessed at baseline. Smoking status was assessed using questionnaire data. Body mass
index (BMI) was calculated as the ratio of weight in kilogram to height in squared metres. Obesity was
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defined as a BMI ⩾30 kg·m−2. Age was categorised into decades and smoking status reported as current,
past and never smokers. Use of ACE inhibitors was determined using questionnaire data [20]. COPD cases
were identified using spirometry data and medical records [21]. Asthma cases were validated based on
medical records [22]. Participants who had both asthma and COPD at baseline were classified as having
asthma–COPD overlap (ACO). Chronic rhinosinusitis and GORD were identified using pharmacy data.
We reviewed the number of prescriptions a participant received within 1 year prior to baseline. Subjects
who got at least two prescriptions of nasal steroids (Anatomical Therapeutic Chemical code (ATC)
R01AD), within 1 year prior to baseline, were considered to have chronic rhinosinusitis. GORD was also
defined as having more than two prescriptions of medications for acid-related disorders such as peptic
ulcer or reflux disease (ATC A02B) within 1 year prior to baseline.
Statistical analyses
The baseline characteristics of the study population were presented using descriptive statistics and
compared using the Mann–Whitney test for skewed continuous variables, Chi-squared test for categorical
variables and t-test for normally distributed continuous data. The prevalence of chronic cough was
calculated as the proportion of patients with chronic cough at baseline expressed in percentages with
corresponding 95% confidence intervals. The prevalence of chronic cough was reported, categorised by
age, sex, smoking status, obesity and comorbidities (ACO, COPD, asthma, GORD and chronic sinusitis).
The prevalence of chronic cough in these categories were compared using Chi-squared tests. To determine
the number of subjects at risk of incident chronic cough, participants with prevalent chronic cough at
baseline were excluded. Incidence rates of chronic cough were calculated by dividing the number of
incident cases by the total number of person years of subjects at risk and reported per 1000 person years.
The 95% confidence intervals of the incidence rates were calculated using a Poisson distribution. Incidence
rates were reported for age, sex, smoking status, obesity and comorbidities. The incidence rate of chronic
cough between groups were compared with incidence rate ratio (IRR) estimated by Poisson regression. We
calculated the incidence rate of chronic cough in participants with complete follow up and also in all the
participants eligible for follow up, as a sensitivity analysis. For the sensitivity analysis, we defined follow up
as the time period between the first round of home interview and death, date of last contact with the
research centre or the end of the study ( June 31, 2014) whichever came first. There were no acute calendar
dates of onset of chronic cough; therefore, we performed logistic regression (instead of Cox regression) to
determine the risk factors of chronic cough and adjusted for sex, smoking, comorbidities and potential
confounders. Statistical significance was considered at a p-value of <0.05. Statistical analyses were
performed using SPSS statistical software (SPSS for Windows, version 24; SPSS; Chicago, IL, USA) and
R-software (The R Project for Statistical computing; www.r-project.org).
Results
Baseline characteristics
Of the 14926 subjects in the Rotterdam Study, 2998 persons (20.0%) died and 28 individuals (<1%) left
the study before the first interview on chronic cough. About 80% of the total cohort (n=11900) were
invited to participate in the first interview; 9984 subjects out of 11900 invitees actually participated,
representing a participation rate of 83.9%. Also, 98.4% (n=9824) of the participants responded to the
chronic cough questionnaire administered during the first interview.
The baseline characteristics of the study population are shown in table 1. Figure 1 depicts the
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) study flow chart. The
mean±SD age of the study population was 66.0±10.8 years and 58.3% (n=5725) of them were women.
Subjects with baseline chronic cough were more frequent in the eighth decade and above (p<0.001) and
had significantly more often a history of current smoking (p<0.001), use of ACE inhibitors (p<0.001), and
comorbidities (p<0.001). There were 37737 years of observation for 6245 participants with complete
follow-up. Of the 8751 participants without baseline chronic cough and who were eligible for follow-up,
1480 (16.9%) participants died during follow-up and 1026 (11.7%) participants were unavailable at the end
of the follow-up period.
Prevalence of chronic cough
The overall baseline period prevalence of chronic cough in the cohort was 10.9% (95% CI 10.3–11.6). The
prevalence of chronic cough increased with age and peaked in the eighth decade (See fig. 2 and table 2).
Although there were no significant sex-specific differences in the prevalence of chronic cough in the
overall study population (p=0.369), in subjects younger than 70 years, the prevalence of chronic cough was
significantly higher in women (10.2%, 95% CI 9.2–11.3) than in men (8.5%, 95% CI 7.4–9.6); p=0.023.
Generally, the prevalence of chronic cough was significantly higher in current smokers (18.6%, 95% CI
16.8–20.5) than in never smokers (8.6%, 95% CI 7.6–9.6), p<0.001; and in ACE inhibitors users
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(13.3%, 95% CI 11.8–14.9) than in non-users (10.4%, 95% CI 9.7–11.1), p<0.001; but not significantly
different in past smokers (9.7%, 95% CI 8.9–10.5) compared to never smokers (8.6%, 95% CI 7.6–9.6),
p=0.620; or in obese subjects (11.4%, 95% CI 10.0–12.8) compared to non-obese subjects (10.3%, 95% CI
9.5–11.0), p=0.154. The prevalence of chronic cough according to comorbidities were as follows: 14.8%
(95% CI 12.9–16.8) in GORD, 19.7% (95% CI 15.3–24.8) in chronic rhinosinusitis, 23.8% (95% CI
20.2–27.6) in asthma, 33.0% (95% CI 29.4–36.7) in COPD, and 28.6% (95% CI 11.3–52.2) in ACO.
Incidence rate of chronic cough
During a mean follow-up of 6 years, 439 incident cases of chronic cough occurred with an overall
incidence rate of 11.6 per 1000 person-years (95% CI 10.6–12.8). As highlighted in table 3 and figure 3,
there were no significant age-specific (IRR 0.93, 95% CI 0.75–1.15) or sex-specific (IRR 0.95, 95% CI
0.79–1.16) differences in the incidence rate of chronic cough in the overall study population. The
incidence rate of chronic cough was higher in obese subjects than in non-obese subjects (IRR 1.27, 95% CI
1.02–1.58) and in current smokers than in never smokers (IRR 1.57, 95% CI 1.20–2.07). Notably, in
current smokers, the incidence of chronic cough was higher in men than in women (IRR 1.92, 95% CI
1.25–2.96). The incidence rate of chronic cough according to comorbidities were as follows: 15.2 per 1000
person-years (95% CI 11.9–19.2) in GORD, 15.1 per 1000 person-years (95% CI 8.7–24.6) in chronic
rhinosinusitis, 26.2 per 1000 person-years (95% CI 19.5–34.5) in asthma, 23.9 per 1000 person-years (95%
CI 16.7–33.3) in COPD, and 33.9 per 1000 person-years (95% CI 4.1–122.5) in ACO. The results of the
sensitivity analysis followed a similar trend as the results in the participants with complete follow-up
except that the incidence rate of chronic cough decreased with age (IRR 0.64, 95% CI 0.52–0.79). Other
details are shown in table 4.
Risk factors for chronic cough
As shown in table 5, The age- and sex-adjusted odds ratios for incident chronic cough was significant in
current smokers (OR 1.63, 95% CI 1.23–2.16), and in subjects with obesity (OR 1.30, 95% CI 1.04–1.62),
GERD (OR 1.42, 95% CI 1.09–1.86), asthma (OR 2.73, 95% CI 1.98–3.75), and COPD (OR 2.42, 95% CI
1.66–3.53). Furthermore, all determinants (age, sex, smoking status, obesity, chronic rhinosinusitis, GERD,
TABLE 1 Baseline characteristics of the study population
Baseline characteristics Total Chronic cough cases Non-cases p-value
Subjects n 9824 1073 8751
Age years 66.0±10.8 67.8±10.6 65.8±10.8 0.392
Age ⩾70 years
No 6118 (62.3) 579 (54.0) 5539 (63.3) <0.001
Yes 3706 (37.7) 494 (46.0) 3212 (36.7)
Age (decades)
5th 570 (5.8) 39 (3.6) 531 (6.1) <0.001
6th 2297 (23.4) 209 (19.5) 2088 (23.9)
7th 3251 (33.1) 331 (30.8) 2920 (33.4)
8th 2453 (25.0) 338 (31.5) 2115 (24.2)
⩾9th 1253 (12.8) 156 (14.5) 1097 (12.5)
Female sex 5725 (58.3) 639 (59.6) 5086 (58.1) 0.369
Smoking
Never 3133 (31.9) 268 (25.0) 2865 (32.8) <0.001
Past 4915 (50.0) 475 (44.3) 4440 (50.8)
Current 1769 (18.0) 329 (30.7) 1440 (16.5)
BMI kg·m−2 27.1 (24.7–29.9) 27.2 (24.6–30.4) 27.0 (24.7–29.8) 0.475
Obesity 2114 (21.5) 240 (22.4) 1874 (21.4) 0.154
ACE inhibitors 1837 (18.7) 244 (22.7) 1593 (18.2) <0.001
Comorbidities 2420 (24.6) 480 (44.7) 1940 (22.2) <0.001
Chronic rhinosinusitis 289 (2.9) 57 (5.3) 232 (2.7) <0.001
GORD 1324 (13.5) 196 (18.3) 1128 (12.9) <0.001
Asthma 522 (5.3) 124 (11.6) 389 (4.5) <0.001
COPD 646 (6.6) 213 (19.9) 433 (4.9) <0.001
ACO 21 (0.2) 6 (0.6) 15 (0.2) 0.009
Data are presented as mean±SD, n (%) or median (interquartile range), unless otherwise stated. BMI: body
mass index; ACE: angiotensin converting enzyme; GORD: gastro-oesophageal reflux disease; COPD:
chronic obstructive pulmonary disease; ACO: asthma–COPD overlap.
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asthma, and COPD) were included in the multivariable model. The result showed that the risk of
developing chronic cough was significantly increased in current smokers (OR 1.64, 95% CI 1.22–2.19), and
in subjects with GERD (OR 1.34, 95% CI 1.01–1.78), asthma (OR 2.88, 95% CI 2.07–4.02), and COPD
(OR 2.52, 95% CI 1.70–3.71). Moreover, the risk for chronic cough in subjects with obstructive airway
disease (asthma, COPD, and ACO) was significantly increased (OR 2.75, 95% CI 2.12–3.58).
Discussion
In this large prospective population-based cohort study, we investigated the prevalence and incidence of,
and risks factors for chronic cough in a community-dwelling middle-aged and older population. Our
results showed that the prevalence of chronic cough in the adult population is approximately 11% with an
estimated incidence rate of 11.6 per 1000 person-years. In addition, current smoking, GORD, COPD and
asthma were independent risk factors for chronic cough in our study population.
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FIGURE 1 STROBE Study flow chart.
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The majority of patients seeking medical attention for chronic cough in out-patient clinics are adults [23].
We found that one in nine adults has chronic cough. Our finding is similar to the global prevalence of
10% and slightly lower than the estimated prevalence in Europe which is 12.7% [2]. FORD et al. [24]
reported a prevalence of 12% in the adult UK population enrolled in a Helicobacter pylori screening and
treatment programme. Moreover, the reported high prevalence of chronic cough in that study could be
due to an expected higher prevalence of GORD in the selected population. Also, a lower prevalence of 4%
was reported in 14669 Danish subjects [25]. However, in that population, subjects had a lower median age
(58 years) than in our study population (mean age 66 years). In Finland, the point prevalence of daily
chronic cough was 7.2% [26]. The study included a defined population of relatively young (baseline age
50.5±10.1 years) Finnish adult employees with a low prevalence of smoking (ever smokers – 30.7%). In
TABLE 2 Baseline prevalence of chronic cough







Study Population 9824 1073 10.9 (10.3–11.6)
Sex
Male 4099 434 10.6 (9.7–11.6) 0.369
Female 5725 639 11.2 (10.4–12.0)
Age ⩾70 years
No 6118 579 9.5 (8.7–10.2) <0.001
Yes 3706 494 13.3 (12.3–14.5)
Age <70 years
Male 2640 224 8.5 (7.4–9.6) 0.023
Female 3478 355 10.2 (9.2–11.3)
Smoking status
Never 3133 268 8.6 (7.6–9.6) <0.001
Past 4915 475 9.7 (8.9–10.5)
Current 1769 329 18.6 (16.8–20.5)
ACE-inhibitors
Non-users 7987 829 10.4 (9.7–11.1) <0.001
Users 1837 244 13.3 (11.8–14.9)
Obesity
No 6618 679 10.3 (9.5–11.0) 0.154
Yes 2114 240 11.4 (10.0–12.8)
ACE: angiotensin converting enzyme













Participants 6245 439 37737 11.6 (10.6–12.8)
Sex
Male 2634 190 15887 12.0 (10.3–13.8) Ref.
Female 3611 249 21850 11.4 (10.0–12.9) 0.95 (0.79–1.16)
Age ⩾70 years
No 4546 318 26811 11.9 (10.6–13.2) Ref.
Yes 1699 121 10926 11.1 (9.2–13.2) 0.93 (0.75–1.15)
Smoking status
Never 2060 129 12427 10.4 (8.7–12.3) Ref.
Past 3216 216 19559 11.0 (9.7–12.6) 1.06 (0.85–1.33)
Current 968 94 5746 16.4 (13.4–20.0) 1.57 (1.20–2.07)
Current smokers
Female 579 41 3435 11.9 (8.6–16.2) Ref.
Male 389 53 2311 22.9 (17.2–30.0) 1.92 (1.25–2.96)
Obesity
No 4549 299 27517 10.9 (9.7–12.2) Ref.
Yes 1440 120 8676 13.8 (11.5–16.5) 1.27 (1.02–1.58)
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contrast, our study consisted of older subjects (baseline age 66.0±10.8 years) from the general population
with a high prevalence of smoking (ever smokers: 68.0%).
Chronic cough is preponderant in females and the cough reflex is more sensitive in women [27]. We
found that chronic cough was more prevalent in women in subjects below 70 years of age. Nevertheless,
there were no significant sex-specific differences in the prevalence of chronic cough in the overall study
population. Similarly, SONG et al. [6] found no significant differences in the sex-specific prevalence of
chronic cough. We observed that the prevalence of chronic cough increased with age and that chronic
cough was more prevalent in subjects aged 70 years and above. Likewise, the results of the Korean
National Health and Nutrition Examination Survey showed that chronic cough was more prevalent in
elderly subjects [28].
The risk factors for chronic cough in adults have been reported in the medical literature [2]. However,
most of these studies were mainly cross-sectional surveys and thus, gave limited insight into the aetiology
of chronic cough. The prospective design of our study enabled us to reliably estimate the incidence of, and
the risk factors for, chronic cough. Our study showed that about 12 out of 1000 adults develop chronic
cough annually. Although the risk of smoking-related morbidity and mortality is known to be higher in
women [29], we found that, in current smokers, the incidence of chronic cough was higher in men. This is
plausible considering that current smoking, a strong independent risk factor for chronic cough, is more
prevalent in men [6, 30].
FIGURE 3 Age-specific incidence of
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Total participants n 8751 439 52817 8.3 (7.6–9.1)
Sex
Male 5086 249 31136 8.0 (7.0–9.1) Ref.
Female 3665 190 21681 8.8 (7.6–10.1) 1.09 (0.90–1.33)
Age ⩾70 years
No 4546 318 33157 11.9 (10.6–13.2) Ref.
Yes 1699 121 19660 11.1 (9.2–13.2) 0.64 (0.52–0.79)
Smoking status
Never 2865 129 17630 7.3 (6.1–8.7) Ref.
Past 4440 216 26736 8.1 (7.0–9.2) 1.10 (0.88–1.38)
Current 1440 94 8433 11.2 (9.0–13.6) 1.52 (1.16–2.00)
Current smokers
Female 857 41 5077 8.1 (5.8–11.0) Ref.
Male 583 53 3355 15.8 (11.8–20.7) 1.96 (1.28–3.02)
Obesity
No 5939 299 36036 8.3 (7.4–9.3) Ref.
Yes 1874 120 11496 10.4 (8.7–12.5) 1.26 (1.01–1.56)
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Furthermore, current smoking, GORD, asthma and COPD were independent risk factors for chronic
cough in our study population. Our findings are in line with the results of previous epidemiological
studies on chronic cough [25, 31]. Smoking is an important risk factor for chronic cough and current
smokers are known to have an increased cough frequency [32, 33]. Also, GORD has been reported as the
third most important medical condition associated with chronic cough in Europe [11]. More still, chronic
cough is not only common but also associated with a more severe clinical outcome in patients with
obstructive airway disease [34, 36]. In our study, chronic cough was most prevalent in COPD patients and
new cases of chronic cough occurred most in subjects with asthma. On the whole, obstructive airway
disease was the most important risk factor for chronic cough in our study population.
The strength of the Rotterdam Study is its prospective, population-based design with long follow-up time
and similar data collection procedures for every subject. Measurement of variables were independent of the
research question thereby making them less susceptible to selection and information bias. In addition, the
effect of selection bias is less likely due to the high response rate (98%) to the questionnaire on chronic
cough.
Like most observational studies, this study is not without potential limitations. First, the Rotterdam Study
adopted a duration of 3 months and a two-year period for defining chronic cough; which was the most
commonly used epidemiological definition at the time of data collection [2]. Nevertheless, it differs from
the criterion of current clinical guidelines (duration of ⩾8 weeks); moreover, the two-year period is
susceptible to recall bias. However, the meta-analysis by SONG et al. [6] showed that the prevalence data
from studies using either the 8 weeks’ or 3 months’ duration, to define chronic cough, fell within the
regional estimates. Importantly, our estimated prevalence of chronic cough (10.9%) is consistent with the
reported pooled prevalence of chronic cough in Europe (12.7% (95% CI 10.4–15.2%)) [2]. Therefore, the
effect of this limitation is expected to be minimal. Secondly, it was not possible for us to report the point
prevalence of chronic cough; hence, we estimated a period prevalence that covered any episode of chronic
cough that occurred within the previous 24 months before the time of the survey. Thirdly, we had a
considerable attrition rate (28.6%), due to mortality and lost to follow-up, and this could have led to
underestimation of the incidence rate and risk of chronic cough in this population. However, we used
person-years rather than persons as denominator to ensure an accurate estimation of the incidence (rate)
of chronic cough. Also, the results of our sensitivity analysis including all participants eligible for follow
up had a similar trend with the findings in subjects with complete follow-up. Therefore, the impact of the
attrition on the estimation of incidence and risk of chronic cough is expected to be minimal. Fourthly, due
to lack of data on chronic rhinosinusitis and GERD, we used medication for these indications as a proxy
to identify subjects with these medical conditions. This may have resulted in misclassification of disease as
subjects with fewer prescriptions may be under-diagnosed and those with more prescriptions
over-diagnosed. Fifthly, incident chronic cough was assessed after 6 years (mean duration) of follow-up
and we did not have information on the exact date of first diagnosis of chronic cough. Hence, the
person-years from baseline to second interview date was used and this may have led to a slight
underestimation of incidence rate of chronic cough in this population.







Model 1 OR (95% CI)
(adjusted)
Model 2 OR (95% CI)
(adjusted)
Subjects n 439 5806
Age years NA NA 1.00 (0.99–1.01) #1.01 (0.99–1.02) 1.00 (0.99–1.01)
Female sex 249 3362 0.95 (0.78–1.16) ¶0.95 (0.78 –1.16) 0.90 (0.73–1.10)
Past smokers 216 3000 1.08 (0.86–1.35) 1.06 (0.84–1.34) 1.00 (0.79–1.27)
Current smokers 94 874 1.61 (1.22–2.13) 1.63 (1.23–2.16) 1.64 (1.22–2.19)
Obesity 120 1320 1.29 (1.04–1.61) 1.30 (1.04–1.62) 1.24 (0.99–1.55)
CRS 16 161 1.33 (0.79–2.24) 1.34 (0.79–2.26) 0.96 (0.54–1.69)
GORD 71 695 1.42 (1.09–1.85) 1.42 (1.09–1.86) 1.34 (1.01–1.78)
OAD 88 480 2.78 (2.16–3.58) 2.79 (2.17–3.60) 2.75 (2.12–3.58)
Asthma 51 272 2.67 (1.95–3.67) 2.73 (1.98–3.75) 2.88 (2.07–4.02)
COPD 35 200 2.43 (1.67–3.53) 2.42 (1.66–3.53) 2.52 (1.70–3.71)
Model 1: adjusted for age and sex; model 2 (full model): adjusted for age, sex, smoking, obesity, chronic obstructive pulmonary disease
(COPD), asthma, gastro-oesophageal reflux disease (GORD) and chronic rhinosinusitis (CRS). Asthma-COPD overlap (ACO) was omitted from
the analyses due to low power (10 subjects). OAD: obstructive airway disease (asthma, COPD and ACO). #: adjusted for sex and smoking.
¶: adjusted for age and smoking.
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In conclusion, chronic cough is common among adults and highly prevalent in the older population.
Smoking, GORD, and obstructive airway disease are independent risk factors of chronic cough. Individuals at
risk of developing chronic cough may benefit from smoking cessation and control of underlying diseases.
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